Indication
Kaposi's sarcoma skin lesion
A Kaposi's sarcoma skin lesion is a primary cutaneous manifestation of Kaposi sarcoma, a multifocal angioproliferative neoplasm driven by infection with human herpesvirus 8 (HHV-8/KSHV). Read more about Kaposi's sarcoma skin lesion
4 drugs 4 manufacturers
Drugs that treat it
Common Kaposi's sarcoma skin lesion therapies.
PANRETIN (alitretinoin)
PANRETIN (alitretinoin)
PANRETIN (alitretinoin)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonA Kaposi's sarcoma skin lesion is a primary cutaneous manifestation of Kaposi sarcoma, a multifocal angioproliferative neoplasm driven by infection with human herpesvirus 8 (HHV-8/KSHV).
It primarily impacts the integumentary system, most commonly arising in immunocompromised populations—such as individuals with advanced HIV infection or organ transplant recipients—as well as older Mediterranean or Eastern European men and endemic populations in Africa.
Clinically, these lesions present as solitary or multiple non-blanching macules, patches, plaques, or nodular tumors that are typically red, purple, brown, or violaceous.
Pathophysiologically, they are characterized by aberrant angiogenesis, spindle-shaped endothelial cell proliferation, extravasated erythrocytes, and intracellular or interstitial hemosiderin deposition.
- nih.gov
A Kaposi's sarcoma skin lesion is a primary cutaneous manifestation of Kaposi sarcoma, a multifocal angioproliferative neoplasm driven by infection with human herpesvirus 8 (HHV-8/KSHV) Pathophysiologically, they are characterized by aberrant angiogenesis, spindle-shaped endothelial cell proliferation, extravasated erythrocytes, and intracellular or interstitial hemosiderin deposition
- nih.gov
A Kaposi's sarcoma skin lesion is a primary cutaneous manifestation of Kaposi sarcoma, a multifocal angioproliferative neoplasm driven by infection with human herpesvirus 8 (HHV-8/KSHV) Clinically, these lesions present as solitary or multiple non-blanching macules, patches, plaques, or nodular tumors that are typically red, purple, brown, or violaceous
- nih.gov
It primarily impacts the integumentary system, most commonly arising in immunocompromised populations—such as individuals with advanced HIV infection or organ transplant recipients—as well as older Mediterranean or Eastern European men and endemic populations in Africa
- nih.gov
It primarily impacts the integumentary system, most commonly arising in immunocompromised populations—such as individuals with advanced HIV infection or organ transplant recipients—as well as older Mediterranean or Eastern European men and endemic populations in Africa
- medlineplus.gov
Clinically, these lesions present as solitary or multiple non-blanching macules, patches, plaques, or nodular tumors that are typically red, purple, brown, or violaceous Pathophysiologically, they are characterized by aberrant angiogenesis, spindle-shaped endothelial cell proliferation, extravasated erythrocytes, and intracellular or interstitial hemosiderin deposition
Personalize your experience
Follow Kaposi's sarcoma skin lesion and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.